X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties ...

the primary autoimmune neutropenia mediated by autoantibodies against mature neutrophils and/or their bone marrow progenitor/precursor cells; and second, the previously named chronic idiopathic ...

The initiation of this trial was a significant milestone for the chronic neutropenia community that – unfortunately – hasn’t seen any treatment innovation in nearly 30 years,” said Paula ...

XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Licensing Agreement with Norgine Includes €28.5 Million  Upfront Payment On January 13, 2025, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced ...

The initiation of this trial was a significant milestone for the chronic neutropenia community that - unfortunately - hasn't seen any treatment innovation in nearly 30 years,” said Paula Ragan, Ph.D., ...

X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered ...

The condition can increase the risk of infections. Neutropenia or low levels of neutrophils, primarily results from chemotherapy. It could also result from conditions that disrupt normal ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.